Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses

Cancer Science

Volumn 106, Issue 5, 2015, Pages 505-511

  Nishimura, Yasuharu ^a   Tomita, Yusuke ^a   Yuno, Akira ^a   Yoshitake, Yoshihiro ^a,b   Shinohara, Masanori ^a,b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Itoh Dento Maxillofacial Hospital   (Japan)

Author keywords

Cancer immunotherapy; cDNA microarray analysis; CTL epitope; Helper T cell epitope; Tumor associated antigen

Indexed keywords

CANCER VACCINE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; PEPTIDE VACCINE; TUMOR ANTIGEN; EPITOPE; PEPTIDE;

ARTICLE; BILE DUCT CARCINOMA; BLADDER CANCER; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; DNA MICROARRAY; ESOPHAGUS CANCER; GENETIC ASSOCIATION; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; NEOPLASM; NON SMALL CELL LUNG CANCER; NONHUMAN; OSTEOSARCOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; SMALL CELL LUNG CANCER; TH1 CELL; TRANSGENIC MOUSE; VACCINATION; ANIMAL; CARCINOMA, SQUAMOUS CELL; CYTOTOXIC T LYMPHOCYTE; GENETICS; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; EPITOPES; GENOME-WIDE ASSOCIATION STUDY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; MICE, TRANSGENIC; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 84929710111     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12650     Document Type: Article

References (57)

1. Couzin-Frankel J. Breakthrough of the year "Cancer Immunotherapy". Science 2013; 342: 1432-3.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
3. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus Ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-33.
4. Snyder A, Makarov V, Merghoub T et al. Genetic basis for clinical response to CTLA-4 blochade in melanoma. N Engl J Med 2014; 371: 2189-99.
5. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
6. Brahmer JR, Tykodi SS, Chow LQM et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-65.
7. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-15.
8. Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18: 1254-61.
9. Saito-Hisaminato A, Katagiri T, Kakiuchi S, Nakamura T, Tsunoda T, Nakamura Y. Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray. DNA Res 2002; 9: 35-45.
10. Okabe H, Satoh S, Kato T et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001; 61: 2129-37.
11. Nakamura T, Furukawa Y, Nakagawa H et al. Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 2004; 23: 2385-400.
12. Hayama S, Daigo Y, Kato T et al. Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res 2006; 66: 10339-48.
13. Ishikawa N, Takano A, Yasui W et al. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 2007; 67: 11601-11.
14. Yamabuki T, Daigo Y, Kato T et al. Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas. Int J Oncol 2006; 28: 1375-84.
15. Firat H, Garcia-Pons F, Tourdot S et al. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol 1999; 29: 3112-21.
16. Jung KO, Khan AM, Tan BY et al. West nile virus T-cell ligand sequences shared with other flaviviruses: a multitude of variant sequences as potential altered Peptide ligands. J Virol 2012; 86: 7616-24.
17. Yoshitake Y, Nakatsura T, Monji M et al. Proliferation potential-related protein, an ideal esophageal cancer antigen for immnotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res 2004; 10: 6437-48.
18. Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 2007; 10: 1803-8.
19. Harao M, Hirata S, Irie A et al. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Int J Cancer 2008; 23: 2616-25.
20. Tomita Y, Harao M, Senju S et al. Peptides derived from human insulin-like growth factor (IGF)-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells. Cancer Sci 2011; 102: 71-8.
21. Tomita Y, Imai K, Senju S et al. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T lymphocytes reactive to tumor cells. Cancer Sci 2011; 102: 697-705.
22. Yokomine K, Senju S, Nakatsura T et al. The Forkhead Box M1 Transcription Factor, as a Possible Immunotherapeutic Tumor-Associated Antigen. Int J Cancer 2010; 126: 2153-63.
23. Inoue M, Senju S, Hirata S et al. Identification of SPARC as a candidate target antigen for immunotherapy of various cancers. Int J Cancer 2010; 127: 1393-403.
24. Komori H, Nakatsura T, Senju S et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12: 2689-97.
25. Imai K, Hirata S, Irie A et al. Identification of a novel tumor-associated antigen, Cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric and colorectal cancers. Clin Cancer Res 2008; 14: 6487-95.
26. Imai K, Hirata S, Irie A et al. Identification of HLA-A2-restricted CTL epitopes of a novel tumor-associated antigen, KIF20A, overexpressed in pancreatic cancer. Br J Cancer 2011; 104: 300-7.
27. Osawa R, Tsunoda T, Yoshimura S et al. Identification of HLA-A24-restricted novel T Cell epitope peptides derived from P-cadherin and kinesin family member 20A. J Biomed Biotechnol 2012; 2012: 848042.
28. Kono K, Mizukami Y, Daigo Y et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009; 100: 1502-9.
29. Kono K, Iinuma H, Akutsu Y et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 2012; 10: 141.
30. Iwahashi M, Katsuda M, Nakamori M et al. Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci 2010; 101: 2510-7.
31. Suzuki H, Fukuhara M, Yamaura T et al. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J Transl Med 2013; 11: 97.
32. Yoshitake Y, Fukuma D, Yuno A et al. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res 2015; 21: 312-21.
33. Yoshitake Y, Nishimura Y, Nakamura Y, Shinohara M [Authors' View]. A clinical trial of multiple peptides vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS. OncoImmunology 2015; doi: 10.1080/2162402X.2015.1022307.
34. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008; 8: 351-60.
35. Melief CJ. "License to kill" reflects joint action of CD4 and CD8 T cells. Clin Cancer Res 2013; 19: 4295-6.
36. + T cell sequestration, dysfunction and deletion. Nat Med 2013; 19: 465-72.
37. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003; 300: 337-9.
38. Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004; 4: 595-602.
39. + cytotoxic T lymphocytes in the control of viral diseases and cancer. Int Rev Immunol 2010; 29: 371-402.
40. Church SE, Jensen SM, Antony PA, Restifo NP, Fox BA. Tumor-specific CD4 T cells maintain effector and memory tumor-specific CD8 T cells. Eur J Immunol 2014; 44: 69-79.
41. + T lymphocytes. Cancer Res 2010; 70: 8368-77.
42. Weide B, Zelba H, Derhovanessian E et al. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 2012; 30: 1835-41.
43. Godet Y, Fabre E, Dosset M et al. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res 2012; 18: 2943-53.
44. Bindea G, Mlecnik B, Tosolini M et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39: 782-95.
45. Wang P, Sidney J, Kim Y et al. Peptide binding predictions for HLA DR. DP and DQ molecules. BMC Bioinformatics 2010; 11: 568.
46. Saito S, Ota S, Yamada E, Inoko H, Ota M. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens 2000; 56: 522-9.
47. + T-cell epitopes. Oncoimmunology 2014; 3: e28100-1-15.
48. + T-cell immunity in cancer patients. Int J Cancer 2014; 134: 352-66.
49. + T-cell immunity in patients with malignant tumor. Clin Cancer Res 2013; 19: 4508-20.
50. Ribas A, Timmerman JM, Butterfield LH, Economou JS. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 2003; 24: 58-61.
51. Corbiere V, Chapiro J, Stroobant V et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res 2011; 71: 1253-62.
52. Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361: 1838-47.
53. Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin Cancer Res 2011; 17: 4568-80.
54. Brunsvig PF, Kyte JA, Kersten C et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res 2011; 17: 6847-57.
55. + T-cell responses in the majority of vaccinated cancer patients. Int J Cancer 2012; 131: 140-9.
56. + T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 2013; 73: 19-29.
57. + T cells in a patient with epithelial cancer. Science 2014; 344: 641-5.